Avience Biomedicals H1 PAT rises 22% as revenue grows 16%
Key highlights
- Avience Biomedicals reported H1 FY27 revenue of Rs 31.1286 crore, up 16.07% year on year.
- Avience Biomedicals’ H1 FY27 PAT rose 22.00% to Rs 5.5362 crore.
- PAT margin increased to 17.78% from 16.92%, while EBITDA margin declined to 26.93% from 27.04%.
- Manufacturing revenue rose 73.36% to Rs 11.2262 crore, while trading revenue declined 2.17% to Rs 19.9024 crore.
powered by IRIS

Avience Biomedicals Limited reported profit after tax (PAT) of Rs 5.5362 crore in H1 FY27, up 22.00% year on year, while revenue rose 16.07% to Rs 31.1286 crore and PAT margin increased to 17.78%. The profit increase exceeded sales growth despite a 0.11-percentage-point decline in EBITDA margin.
Know Avience Biomedicals inside out
Results, valuation, peers and who's buying, in one view.
How did Avience Biomedicals perform in H1 FY27?
Avience Biomedicals increased revenue, earnings before interest, tax, depreciation and amortisation (EBITDA), and PAT in H1 FY27, with PAT growing fastest. Revenue rose from Rs 26.8193 crore in H1 FY26 to Rs 31.1286 crore, an increase of Rs 4.3093 crore. EBITDA increased from Rs 7.2529 crore to Rs 8.3843 crore, while PAT rose from Rs 4.5378 crore to Rs 5.5362 crore, according to the H1 FY27 performance snapshot.
PAT growth was 5.93 percentage points above revenue growth and 6.40 percentage points above EBITDA growth in H1 FY27. EBITDA growth of 15.60% was marginally below the 16.07% increase in revenue, while PAT grew 22.00%. This comparison shows that the period’s profit gain was faster than the top-line gain, although the presentation does not provide an income-statement bridge identifying the movements between EBITDA and PAT.
The company operates in in-vitro diagnostics (IVD) products and medical devices, manufacturing and distributing reagents, analysers and consumables. Its business model includes installing diagnostic instruments at customer locations and generating repeat purchases of reagents and consumables. In H1 FY27, the reported revenue base of Rs 31.1286 crore therefore included both manufacturing and trading activities, which moved in different directions during the period.
Why did Avience Biomedicals’ PAT margin improve in H1 FY27?
Avience Biomedicals’ PAT margin improved by 0.86 percentage points to 17.78% in H1 FY27 from 16.92% in H1 FY26. Management attributed the improvement to disciplined execution and a favourable product mix. On the reported H1 FY27 revenue of Rs 31.1286 crore, PAT was Rs 5.5362 crore, compared with Rs 4.5378 crore on Rs 26.8193 crore of revenue a year earlier.
The change was not uniform across the company’s two reported profitability margins. EBITDA margin declined by 0.11 percentage points to 26.93% in H1 FY27 from 27.04% in H1 FY26, even though EBITDA increased by Rs 1.1314 crore to Rs 8.3843 crore. PAT margin, in contrast, increased by 0.86 percentage points as PAT rose by Rs 0.9984 crore. The presentation does not quantify depreciation, finance cost, tax or other factors that may explain the different margin movements.
Management described H1 FY27 as a period of steady and profitable growth, citing the 16.07% increase in revenue, 15.60% rise in EBITDA and 22.00% increase in PAT. Its commentary linked the 17.78% PAT margin to execution and product mix, rather than setting a future margin target. The disclosed figures therefore establish the reported margin outcome for H1 FY27, but do not specify the contribution of individual products, customers or costs.
Got a follow-up? Ask IRIS
What changed in Avience Biomedicals’ revenue mix?
Avience Biomedicals’ manufacturing revenue rose 73.36% in H1 FY27, while trading revenue declined 2.17%. Manufacturing increased from Rs 6.4753 crore in H1 FY26 to Rs 11.2262 crore, adding Rs 4.7509 crore. Trading declined from Rs 20.3437 crore to Rs 19.9024 crore, a reduction of Rs 0.4413 crore, although it remained the larger reported segment by revenue.
The segment data indicate that the manufacturing increase was the main contributor to the overall revenue rise in H1 FY27, offsetting the small trading decline. The segment table reports total H1 FY26 revenue of Rs 26.8190 crore, while the performance snapshot reports Rs 26.8193 crore, a difference of Rs 0.0003 crore. The company does not explain this difference in the presentation.
Avience Biomedicals also reported a change in its geographic sales mix, with export share rising to 13.53% in H1 FY27 from 1.01% in FY26. Domestic share consequently declined to 86.47% from 98.99%, while the export share increased by 12.52 percentage points. As the comparison is between a full fiscal year and a half-year period, it measures the composition of reported revenue in those respective periods rather than a like-for-like H1 comparison.
What is Avience Biomedicals planning after H1 FY27?
Avience Biomedicals said its fully automated manufacturing facility at YEIDA Medical Device Park on the Yamuna Expressway is on track for completion by January 2027. Management said the facility is set to be inaugurated shortly and is intended to enhance manufacturing capability, particularly in biochemistry analysers and reagents, while providing scale for institutional demand. The presentation gives no capital-cost figure, capacity figure or date for commercial operations.
Product expansion is another management priority, supported by 117 Central Drugs Standard Control Organisation (CDSCO) manufacturing licences. These licences cover biochemistry, rapid diagnostics, haematology and microbiology, and the company said it has more than 200 products under regulatory approval. Management intends to launch products progressively as approvals are received and expand into additional diagnostic categories, making regulatory outcomes a stated dependency of this plan.
The company also said its authorised distributorship of Mindray in India supports analyser placements at customer locations. Management stated that these placements strengthen recurring revenue opportunities from reagents and consumables. With manufacturing revenue at Rs 11.2262 crore in H1 FY27 versus Rs 6.4753 crore a year earlier, the planned facility and approval pipeline are linked to the company’s stated strategy of expanding its manufacturing and diagnostics product base.
Conclusion
Avience Biomedicals delivered H1 FY27 revenue growth of 16.07% to Rs 31.1286 crore and PAT growth of 22.00% to Rs 5.5362 crore. PAT margin rose to 17.78% from 16.92%, while EBITDA margin moved to 26.93% from 27.04%. The revenue mix also shifted as manufacturing grew 73.36% and trading declined 2.17%, alongside an increase in reported export share to 13.53%.
The next disclosed milestones are completion of the YEIDA Medical Device Park facility by January 2027 and regulatory decisions on more than 200 products under approval. Management’s plans identify biochemistry analysers, reagents, additional diagnostic categories and recurring consumables sales as areas to watch, while the presentation leaves capacity, project cost and commercial start-up timing undisclosed.


